PT-141: the complete guide
PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist developed from melanotan II. It acts on central nervous system pathways rather than the vascular system to enhance sexual arousal.
How PT-141 works
PT-141 activates MC3R and MC4R receptors in the hypothalamus, influencing dopaminergic pathways involved in sexual desire in both males and females.
Typical PT-141 dosage
Commonly reported research ranges: 0.5–2 mg (500–2000 mcg) per dose, on demand.
Dose should always be individualized. Factors that influence it include bodyweight, research goal, tolerance, and specific compound batch. The information below is educational, not a prescription.
How to reconstitute PT-141
A widely used reconstitution for a 10 mg vial is 2 ml of bacteriostatic water. With a typical 1000 mcg dose this works out to the unit count shown in the calculator below.
Half-life and administration frequency
Approximately 2 hours.
This half-life informs how often PT-141 is typically dosed. Shorter half-lives usually mean more frequent dosing to maintain plasma levels; longer half-lives allow daily, weekly, or less-frequent administration depending on the compound.
Plot it: the PT-141 half-life and pharmacokinetics chart shows accumulation, steady state, peak and trough for any cadence. Converting between mcg, mg and IU? Use the peptide dose converter.
Reported side effects
- Nausea (common, especially first doses)
- Flushing
- Transient blood pressure increase
- Injection-site reactions
This list reflects effects reported in available literature or user logs. It is not exhaustive. Adverse reactions should be discussed with a qualified clinician.
Common PT-141 stacks
- Typically used alone, on demand
PT-141 compared with
Side-by-side breakdowns against other peptides in the same class or category.
Related peptides
Compounds that come up alongside PT-141 — because they are compared with it, stacked with it, or sit in the same category.
Browse the full peptide glossary, the peptide stack guides, or the reconstitution calculator.
Storage and handling
Lyophilized refrigerated. Reconstituted: refrigerated, use within 28 days.
FDA and regulatory status
FDA approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.
PT-141 clinical trials and evidence
For clinical-trial and primary-literature context, start with the sources below. We prioritize official drug labels, ClinicalTrials.gov records, and PubMed-indexed literature when available.
- Bremelanotide clinical trial records — ClinicalTrials.gov
Track your PT-141 protocol on iPhone
Peptide Protocol logs every dose, calculates reconstitution for you, and keeps your full protocol on one calm screen.
See the app →Frequently asked questions
What is PT-141?
PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist developed from melanotan II. It acts on central nervous system pathways rather than the vascular system to enhance sexual arousal.
How does PT-141 work?
PT-141 activates MC3R and MC4R receptors in the hypothalamus, influencing dopaminergic pathways involved in sexual desire in both males and females.
What is a typical PT-141 dose?
Commonly reported ranges are 0.5–2 mg (500–2000 mcg) per dose, on demand. This is research information, not a recommendation — dosing should be individualized under clinical guidance.
What is the half-life of PT-141?
Approximately 2 hours. This influences how often it is administered.
How do you reconstitute PT-141?
A common approach is to add 2 ml of bacteriostatic water to a 10 mg vial. Use the reconstitution calculator for exact unit counts.
What are the side effects of PT-141?
Nausea (common, especially first doses); Flushing; Transient blood pressure increase; Injection-site reactions.
Is PT-141 FDA approved?
FDA approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Are there clinical trials for PT-141?
Registered or published clinical-trial sources for PT-141 are listed in the references section below. Evidence depth varies widely by compound, so check the cited trial registries and primary literature before relying on any claim.
References
- Bremelanotide (Vyleesi, PT-141) — FDA Drugs@FDA — U.S. Food and Drug Administration. FDA approval for hypoactive sexual desire disorder in premenopausal women
- Bremelanotide pharmacology literature — PubMed. Primary studies on melanocortin agonism and sexual function
- Bremelanotide clinical trial records — ClinicalTrials.gov. Pivotal and supporting trials
Sources listed above were used to verify the claims on this page. See our editorial policy for how we source information.
Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.